{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:56:25Z","timestamp":1790207785015,"version":"4.1.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"DOI":"10.1182\/bloodadvances.2025018090","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T21:05:32Z","timestamp":1763586332000},"page":"1481-1486","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Rapid loss of viability in acute myeloid leukemia cells upon telomerase inactivation"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-5017","authenticated-orcid":false,"given":"Elisa","family":"Aquilanti","sequence":"first","affiliation":[{"name":"1Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Cancer Program, Broad Institute, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9641-4926","authenticated-orcid":false,"given":"Lauren","family":"Kageler","sequence":"additional","affiliation":[{"name":"3Cancer Program, Broad Institute, Cambridge, MA"},{"name":"4Stem Cell Program and Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Bozinov","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Cancer Program, Broad Institute, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Meyerson","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Cancer Program, Broad Institute, Cambridge, MA"},{"name":"5Department of Genetics, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"2026030916213174900_bib1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"issue":"6","key":"2026030916213174900_bib2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","article-title":"Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Tallman","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2026030916213174900_bib3","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","article-title":"Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Heuser","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"2026030916213174900_bib4","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.stem.2014.11.010","article-title":"Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy","volume":"15","author":"Bruedigam","year":"2014","journal-title":"Cell Stem Cell"},{"issue":"1","key":"2026030916213174900_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s43018-023-00653-5","article-title":"Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia","volume":"5","author":"Bruedigam","year":"2024","journal-title":"Nat Cancer"},{"issue":"4","key":"2026030916213174900_bib6","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/blood-2003-12-4322","article-title":"Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532","volume":"105","author":"El-Daly","year":"2005","journal-title":"Blood"},{"issue":"13","key":"2026030916213174900_bib7","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1200\/JCO.2000.18.13.2626","article-title":"Role of telomerase in normal and cancer cells","volume":"18","author":"Meyerson","year":"2000","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026030916213174900_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/07853890109002067","article-title":"Telomerase activation, cellular immortalization and cancer","volume":"33","author":"Hahn","year":"2001","journal-title":"Ann Med"},{"issue":"2 pt 1","key":"2026030916213174900_bib9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0092-8674(85)90170-9","article-title":"Identification of a specific telomere terminal transferase activity in Tetrahymena extracts","volume":"43","author":"Greider","year":"1985","journal-title":"Cell"},{"issue":"7859","key":"2026030916213174900_bib10","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41586-021-03415-4","article-title":"Structure of human telomerase holoenzyme with bound telomeric DNA","volume":"593","author":"Ghanim","year":"2021","journal-title":"Nature"},{"issue":"33","key":"2026030916213174900_bib11","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1038\/sj.onc.1208760","article-title":"Lipid modification of GRN163, an N3\u2032--&gt;P5\u2032 thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition","volume":"24","author":"Herbert","year":"2005","journal-title":"Oncogene"},{"issue":"1","key":"2026030916213174900_bib12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.20.01895","article-title":"Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study","volume":"39","author":"Steensma","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026030916213174900_bib13","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2021-151607","article-title":"Imetelstat significantly reduces leukemia stem cells in patient-derived xenograft models of pediatric AML","volume":"138","author":"Barwe","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2026030916213174900_bib14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s43018-023-00653-5","article-title":"Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia","volume":"5","author":"Bruedigam","year":"2024","journal-title":"Nat Cancer"},{"issue":"10","key":"2026030916213174900_bib15","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1056\/NEJMe1508740","article-title":"Treating myeloproliferation\u2014on target or off?","volume":"373","author":"Armanios","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"2026030916213174900_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","article-title":"The present and future of the cancer dependency map","volume":"25","author":"Arafeh","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"2026030916213174900_bib17","doi-asserted-by":"crossref","first-page":"e66198","DOI":"10.7554\/eLife.66198","article-title":"Integrated evaluation of telomerase activation and telomere maintenance across cancer cell lines","volume":"10","author":"Hu","year":"2021","journal-title":"Elife"},{"issue":"22","key":"2026030916213174900_bib18","doi-asserted-by":"crossref","first-page":"e1658","DOI":"10.21769\/BioProtoc.1658","article-title":"Telomere restriction fragment (TRF) analysis","volume":"5","author":"Mender","year":"2015","journal-title":"Bio Protoc"},{"issue":"17","key":"2026030916213174900_bib19","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood.2021011917","article-title":"Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1\/FLT3-mutated AML","volume":"138","author":"Carter","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2026030916213174900_bib20","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"issue":"3","key":"2026030916213174900_bib21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/ng.3781","article-title":"Systematic analysis of telomere length and somatic alterations in 31 cancer types","volume":"49","author":"Barthel","year":"2017","journal-title":"Nat Genet"},{"issue":"11","key":"2026030916213174900_bib22","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1038\/nprot.2013.132","article-title":"CRISPR interference (CRISPRi) for sequence-specific control of gene expression","volume":"8","author":"Larson","year":"2013","journal-title":"Nat Protoc"},{"issue":"1","key":"2026030916213174900_bib23","doi-asserted-by":"crossref","first-page":"7139","DOI":"10.1038\/s41467-021-27055-4","article-title":"A predominant enhancer co-amplified with the SOX2 oncogene is necessary and sufficient for its expression in squamous cancer","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"2026030916213174900_bib24","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1158\/2159-8290.CD-22-1230","article-title":"A ubiquitination cascade regulating the integrated stress response and survival in carcinomas","volume":"13","author":"Cervia","year":"2023","journal-title":"Cancer Discov"},{"issue":"7","key":"2026030916213174900_bib25","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/neuonc\/noad024","article-title":"Telomerase inhibition is an effective therapeutic strategy in TERT promoter mutant-glioblastoma models with low tumor volume","volume":"25","author":"Aquilanti","year":"2023","journal-title":"Neuro Oncol"},{"issue":"3","key":"2026030916213174900_bib26","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1182\/blood-2002-07-2015","article-title":"Telomerase levels control the lifespan of human T lymphocytes","volume":"102","author":"Roth","year":"2003","journal-title":"Blood"},{"issue":"10","key":"2026030916213174900_bib27","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/13495","article-title":"Inhibition of telomerase limits the growth of human cancer cells","volume":"5","author":"Hahn","year":"1999","journal-title":"Nat Med"},{"issue":"4","key":"2026030916213174900_bib28","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41588-023-01339-5","article-title":"Thymidine nucleotide metabolism controls human telomere length","volume":"55","author":"Mannherz","year":"2023","journal-title":"Nat Genet"},{"issue":"1","key":"2026030916213174900_bib29","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41467-023-36150-7","article-title":"Chromatin complex dependencies reveal targeting opportunities in leukemia","volume":"14","author":"Najm","year":"2023","journal-title":"Nat Commun"},{"issue":"4","key":"2026030916213174900_bib30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0092-8674(00)80762-X","article-title":"p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis","volume":"97","author":"Chin","year":"1999","journal-title":"Cell"},{"issue":"2","key":"2026030916213174900_bib31","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1172\/JCI20761","article-title":"Telomeres, stem cells, senescence, and cancer","volume":"113","author":"Sharpless","year":"2004","journal-title":"J Clin Invest"},{"issue":"5","key":"2026030916213174900_bib32","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"1","key":"2026030916213174900_bib33","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/CCO.0b013e32835b651e","article-title":"Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy","volume":"25","author":"Hainaut","year":"2013","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"2026030916213174900_bib34","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.20.01895","article-title":"Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study","volume":"39","author":"Steensma","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026030916213174900_bib35","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/neuonc\/noab203","article-title":"Telomerase as a therapeutic target in glioblastoma","volume":"23","author":"Aquilanti","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026030916213174900_bib36","doi-asserted-by":"crossref","first-page":"120402","DOI":"10.1016\/j.lfs.2022.120402","article-title":"Telomerase inhibition on acute myeloid leukemia stem cell induced apoptosis with both intrinsic and extrinsic pathways","volume":"295","author":"Rafat","year":"2022","journal-title":"Life Sci"},{"issue":"11","key":"2026030916213174900_bib37","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"23","key":"2026030916213174900_bib38","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1481\/2505464\/blooda_adv-2025-018090-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1481\/2505464\/blooda_adv-2025-018090-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:21:41Z","timestamp":1773087701000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/5\/1481\/548297\/Rapid-loss-of-viability-in-acute-myeloid-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018090","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,10]]},"published":{"date-parts":[[2026,2,25]]}}}